Mumps — branching viva

Opening question

Examiner: Take me through this adolescent. What is the most likely diagnosis, and what is your frame for managing it? [5]

Candidate: The most likely diagnosis is mumps with orchitis. The bilateral parotitis with fever and the severe testicular pain in a postpubertal male, in the setting of a university mumps outbreak, is classic — and the fact that he has had two MMR doses does not exclude it, because waning immunity makes vaccinated young adults the outbreak group. My frame is two-layered: manage this adolescent and his complication now, and run the public-health response to stop transmission. The immediate clinical priority, though, is to exclude testicular torsion, because orchitis and torsion overlap and torsion is the surgical emergency. [5] [2]

Examiner: Why is the postpubertal male at particular risk of orchitis? [5]

Candidate: The mumps virus is tropic for glandular duct epithelium, and in a postpubertal host the testicular tissue is mature enough to be seeded by the viraemia, producing oedema and pressure within the tunica and the painful orchitis. In a prepubertal child the gonadal tissue is immature and orchitis does not occur. The biology of the virus is the same; the host turns a nuisance into a complication. [5]

Branch 1 — pathophysiology

Examiner: Explain the pathophysiology of mumps parotitis. [4]

Candidate: The mumps virus, a paramyxovirus of the genus Rubulavirus, enters via the respiratory tract or conjunctiva and infects nasopharyngeal epithelium. It spreads to the parotid gland via the ductal epithelium of Stensen's duct, then enters the bloodstream in a primary viraemia and seeds its target organs — the salivary and parotid glands, the testes and ovaries, the pancreas, and the central nervous system. In the parotid, interstitial oedema and a periductal mononuclear infiltrate produce the tender swelling. That tropism is why parotitis is the hallmark but also why orchitis, meningitis and pancreatitis arise. [4]

Examiner: Is parotitis required for transmission? [4]

Candidate: No — up to a third of mumps infections are subclinical, with no parotitis at all, yet these individuals still shed virus and can develop the seeded complications. This is why a vaccinated young adult with meningitis or orchitis and an outbreak contact is still mumps until proven otherwise, even without parotid swelling. The clinical diagnosis must rest on the picture and the epidemiology, not on the presence of swollen glands. [4] [5]

Branch 2 — diagnosis

Examiner: How will you confirm mumps in this adolescent? [7]

Candidate: I would send a buccal or oral swab for mumps RT-PCR, which has its highest yield in the first one to three days of parotitis, when viral shedding is greatest. A British Columbia outbreak investigation confirmed that buccal PCR combined with genotyping is the most informative approach in a partially vaccinated population. I would supplement with mumps IgM and IgG serology, and use genotyping to distinguish wild-type from vaccine strain. I would not delay supportive care or isolation while waiting for the result. [7]

Examiner: He has had two MMR doses. How does that affect interpretation of the serology? [7]

Candidate: In a previously vaccinated individual the IgM response may be blunted or absent, so a negative IgM does not exclude mumps during an outbreak. I would build the diagnosis on the clinical picture, the outbreak setting, and PCR with genotyping, rather than on a single negative serological result. Over-reliance on serology in the vaccinated is a recognised diagnostic pitfall. [7]

Branch 3 — management and the scrotal-pain question

Examiner: What is the immediate clinical priority with the testicular pain? [5]

Candidate: To exclude testicular torsion. Mumps orchitis and torsion can overlap, and torsion is the time-critical surgical emergency that cannot wait. I would assess the onset (sudden favours torsion), the cremasteric reflex and the lie of the testis, and, whenever torsion is plausible, arrange urgent surgical assessment rather than attribute the pain to mumps. Once torsion is excluded, the orchitis is managed supportively with scrotal support, analgesia and rest, with honest discussion of atrophy (possible) and sterility (rare). [5]

Examiner: Is there any antiviral or antibiotic you would give? [4]

Candidate: No. There is no antiviral, antibiotic or corticosteroid of proven benefit in mumps. The Cochrane review of MMR vaccines underpins the prevention side, but the treatment is supportive — analgesia, antipyretics, hydration and a soft diet. Stating this honestly — that mumps management is supportive and public-health, not pharmacological — is important, and the decisive interventions are isolation, notification and contact tracing. [4]

Branch 4 — public-health layer

Examiner: Walk me through the infection-control and public-health response. [3]

Candidate: I would place the adolescent under droplet precautions and exclude from university for five days from the onset of parotitis swelling — a duration supported by the Kutty evidence review that justified the change from nine days, reflecting the sharp fall in infectiousness after the first days of parotitis. I would notify public health according to local requirements, because mumps is notifiable, and the notification triggers the contact-tracing and outbreak-control response. I would identify all household and close contacts, and flag who is susceptible — the under-vaccinated, pregnant, and immunocompromised. [3]

Examiner: Who gets a third MMR dose, and why? [1]

Candidate: In an outbreak affecting a dense, two-dose-vaccinated population of older adolescents and young adults, a targeted third MMR dose is an evidence-based control measure. The Cardemil study in the New England Journal of Medicine showed that a third dose reduced the risk of mumps and improved outbreak control in the high-risk university setting. So I would, in coordination with public health, offer a third dose to the high-risk groups in this outbreak, alongside catch-up vaccination for the under-immunised. [1]

Branch 5 — prevention and resurgence

Examiner: He has had two doses. Why is he still at risk, and why does mumps keep coming back? [2]

Candidate: Because immunity wanes over the years after the second dose. Two doses of MMR are about 88% effective, but by late adolescence the residual protection has fallen, and the dense, social settings of university life amplify exposure. The Barskey report of the Orthodox Jewish community outbreak showed that mumps could spread extensively even in a highly two-dose-vaccinated population, and the French waning-immunity reports and the Peltola editorial framed the problem. This is waning immunity, not vaccine failure or strain escape — the Rubin study showed that Jeryl Lynn-induced antibody neutralises heterologous wild-type outbreak strains. [2] [6]

Examiner: So how do we prevent the next case? [1]

Candidate: Through high coverage of the two-dose schedule, catch-up vaccination of the under-immunised at every opportunity, prompt isolation and notification of cases, and a targeted third dose in outbreak settings. Live MMR vaccine is contraindicated in pregnancy and in significant immunocompromise, so those groups depend on the immunity of the people around them — cocooning. The principle is the same everywhere: two doses in childhood, catch-up for the under-immunised, isolation and notification of cases, and a third dose in outbreaks. [1] [4]

Wrap

Examiner: Summarise the mumps stance in one sentence. [4]

Candidate: Recognise the parotitis and its complications early, exclude torsion in the postpubertal male, confirm with buccal RT-PCR and genotyping, treat supportively because there is no antiviral, isolate for five days and notify, prophylax no one pharmacologically but offer a third MMR dose in outbreaks, and prevent the next case with two doses, catch-up and high coverage — because mumps management is supportive and public-health, not pharmacological. [1] [4]